Zanubrutinib Shows Superiority Over Bendamustine-Rituximab in Newly Diagnosed CLL/SLL
Zanubrutinib Shows Long-Term Benefits for Patients with CLL/SLL
New data from the SEQUOIA trial demonstrate the sustained efficacy and safety of zanubrutinib in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
CLL/SLL | Image Credit:
Five-year follow-up data from the phase 3 SEQUOIA trial, presented at the 2024 American Society of hematology (ASH) annual Meeting, showed that patients with previously untreated CLL/SLL who received zanubrutinib experienced considerably longer progression-free survival (PFS) compared to those who received bendamustine plus rituximab (BR).
“These results confirm the long-term benefits of zanubrutinib in treating CLL/SLL,” said Dr. Mehmet Shadman, led author of the study. “Zanubrutinib continues to demonstrate superior PFS regardless of disease risk status and even in the context of the COVID-19 pandemic.”
Zanubrutinib outperforms BR in Key Outcomes
In cohort 1 of the SEQUOIA trial, patients were randomly assigned to receive either zanubrutinib (n=241) or BR (n=238). The median PFS was not reached in the zanubrutinib group compared to 44.1 months in the BR group (hazard ratio [HR], 0.29; 95% CI, 0.21-0.40; P < .0001). Importantly, the PFS benefit of zanubrutinib was consistent across diffrent subgroups, including patients with mutated and unmutated IGHV status, a key prognostic factor in CLL/SLL.
“This suggests that zanubrutinib may overcome negative prognostic factors such as IGHV mutation, del(17p), or TP53 mutation,” Dr. shadman explained.
Zanubrutinib also demonstrated a higher overall response rate (ORR) and a more favorable safety profile compared to BR.
Safety and Tolerability
Zanubrutinib was well-tolerated over the extended treatment period. The most common grade 3 or higher adverse events (AEs) included COVID-19, hypertension, and neutropenia. Notably, rates of atrial fibrillation/flutter, infections, and gastrointestinal toxicities were low.
Next-Generation BTK Inhibitor
Zanubrutinib is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor designed for improved efficacy and tolerability. BTK inhibitors have revolutionized the treatment of CLL/SLL, and zanubrutinib’s enhanced potency, greater BTK specificity, and increased exposure coverage contribute to its superior clinical outcomes.
These findings solidify zanubrutinib as a valuable treatment option for patients with newly diagnosed CLL/SLL, offering the potential for long-term disease control and improved quality of life.
Please provide me with some context or a question so I can assist you. For example, you could ask:
Write me a short story about a cat.
Explain the concept of quantum mechanics.
Translate “hello” into Spanish.
What is the capital of France?
I’m ready too help! 😊